NeuroMetrix Reports Expanded Media Coverage for Quell Wearable Pain Relief

WALTHAM, Mass.–(BUSINESS WIRE)–$NURO #chronicpain–NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) reported increased media
attention on the company’s Quell® Wearable Pain Relief
Technology, including an in depth report on CBS’s Innovation
. Highlights include:

CBS Innovation NationThe
Medicine-Free Pain Relieving Device

MedCity NewsArianna
Huffington Takes on Consumer Wellness

Pain News NetworkQuell
Relieves Back Pain Without Medication

National Pain ReportMy
Favorite Tool for Reducing Fibromyalgia

Fibromyalgia News TodayNeuroMetrix
to Test Quell Pain Relief Device in Fibromyalgia Pilot

Sleep Review Magazine NeuroMetrix
Health Cloud Collects 1 Million Hours Therapy Health Data

MedCity NewsCan
a ‘smart’ pain management system be alternative to opioids for chronic

In addition, Quell has been extensively reviewed by chronic pain
bloggers including: Chronic
, Not
Still Standing
, At
, and The
Disabled Diva

“Chronic pain sufferers are desperate for more effective tools to manage
their condition, and Quell’s 100% drug-free pain relief is resonating,”
said Frank McGillin, Senior Vice President and Chief Commercial Officer
NeuroMetrix. “We are excited about the continued high level of attention
Quell is gaining among consumer, technology and healthcare media. “

About Quell

Quell is designed for millions of people suffering from chronic pain.
The advanced wearable device is lightweight and can be worn during the
day while active, and at night while sleeping. It has been cleared by
the FDA for treatment of chronic pain without a prescription. In a
recent study, 81% of Quell users reported an improvement in their
chronic pain. Quell users can start, stop, and adjust therapy discreetly
via the optional Quell Relief app. Quell also offers advanced sleep
tracking that provides feedback on eight dimensions of sleep including
sleep duration, quality, body position, time out of bed, and repetitive
leg movements throughout the night. Quell was the winner of the 2016
SXSW (South by Southwest) Innovation Award for Best Wearable Technology.
Quell is available at select healthcare professionals and retailers.
for more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company’s lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs, including a therapeutic device for restless
leg syndrome. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit


NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer